Perspectives for angiotensin profiling with liquid chromatography/mass spectrometry to evaluate ACE/ACE2 balance in endothelial dysfunction and vascular pathologies

Pharmacological Reports

Volumn 67, Issue 4, 2015, Pages 778-785

  Olkowicz, Mariola ^a,b   Chlopicki, Stefan ^c,d   Smolenski, Ryszard T ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Angiotensin peptides; Liquid chromatography mass spectrometry; Renin angiotensin system; Vascular injury

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; PRORENIN RECEPTOR; RENIN; ACE PROTEIN, HUMAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD VESSEL CALCIFICATION; BLOOD VESSEL INJURY; ENDOTHELIAL DYSFUNCTION; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SOLID PHASE EXTRACTION; THROMBOSIS; VASCULAR DISEASE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; VASCULITIS; VASOCONSTRICTION; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES; TANDEM MASS SPECTROMETRY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; TANDEM MASS SPECTROMETRY;

EID: 84940462452     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2015.03.017     Document Type: Review

References (75)

1. S. Kim, and H. Iwao Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases Pharmacol Rev 52 1 2000 11 34
2. M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, V. Esteban, Y. Suzuki, S. Mezzano, and et al. Role of the renin-angiotensin system in vascular diseases: expanding the field Hypertension 38 6 2001 1382 1387
3. A.R. Brasier, A. Recinos 3rd, and M.S. Eledrisi Vascular inflammation and the renin-angiotensin system Arterioscler Thromb Vasc Biol 22 8 2002 1257 1266
4. R. Skrbic, and R. Igic Seven decades of angiotensin (1939-2009) Peptides 30 10 2009 1945 1950
5. G. Coppola, G. Romano, E. Corrado, R.M. Grisanti, and S. Novo Peripheral artery disease: potential role of ACE-inhibitor therapy Vasc Health Risk Manag 4 6 2008 1179 1187
6. T. Unger, L. Paulis, and D.A. Sica Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches Eur Heart J 32 22 2011 2739 2747
7. A. Nguyen Dinh Cat, and R.M. Touyz A new look at the renin-angiotensin system - focusing on the vascular system Peptides 32 10 2011 2141 2150
8. A.C. Montezano, A. Nguyen Dinh Cat, F.J. Rios, and R.M. Touyz Angiotensin II and vascular injury Curr Hypertens Rep 16 6 2014 431
9. M. Ruiz-Ortega, M. Ruperez, V. Esteban, and J. Egido Molecular mechanisms of angiotensin II-induced vascular injury Curr Hypertens Rep 5 1 2003 73 79
10. S. Chlopicki, and R.J. Gryglewski Endothelial secretory function and atherothrombosis The eicosanoids 2004 John Wiley & Sons, Ltd. 267 276
11. P.K. Mehta, and K.K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol 292 1 2007 C82 C97
12. T.L. Reudelhuber The renin-angiotensin system: peptides and enzymes beyond angiotensin II Curr Opin Nephrol Hypertens 14 2 2005 155 159
13. E. Kaschina, and T. Unger Angiotensin AT1/AT2 receptors: regulation, signalling and function Blood Press 12 2 2003 70 88
14. R.A. Santos, A.J. Ferreira, T. Verano-Braga, and M. Bader Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system J Endocrinol 216 2 2013 R1 R17
15. D.C. Coutinho, G. Foureaux, K.D. Rodrigues, R.L. Salles, P.L. Moraes, T.M. Murca, and et al. Cardiovascular effects of angiotensin A: a novel peptide of the renin-angiotensin system J Renin Angiotensin Aldosterone Syst 15 4 2014 480 486
16. R.Q. Lautner, D.C. Villela, R.A. Fraga-Silva, N. Silva, T. Verano-Braga, F. Costa-Fraga, and et al. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system Circ Res 112 8 2013 1104 1111
17. G.M. Etelvino, A.A. Peluso, and R.A. Santos New components of the renin-angiotensin system: alamandine and the MAS-related G protein-coupled receptor D Curr Hypertens Rep 16 6 2014 433
18. C. Guang, R.D. Phillips, B. Jiang, and F. Milani Three key proteases - angiotensin-I-converting enzyme (ACE) ACE2 and renin - within and beyond the renin-angiotensin system Arch Cardiovasc Diseases 105 6-7 2012 373 385
19. S.W. Seto, S.M. Krishna, C.S. Moran, D. Liu, and J. Golledge Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein-E-deficient mouse model Clin Sci (Lond) 127 2 2014 123 134
20. M.I. Phillips, and K.M. Schmidt-Ott The discovery of renin 100 years ago Physiology 14 6 1999 271 274
21. M.P. Ocaranza, I. Godoy, J.E. Jalil, M. Varas, P. Collantes, M. Pinto, and et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat Hypertension 48 4 2006 572 578
22. M.P. Ocaranza, L. Michea, M. Chiong, C.F. Lagos, S. Lavandero, and J.E. Jalil Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system Clin Sci (Lond) 127 9 2014 549 557
23. F. Jiang, J. Yang, Y. Zhang, M. Dong, S. Wang, Q. Zhang, and et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets Nat Rev Cardiol 11 7 2014 413 426
24. J. Varagic, S. Ahmad, S. Nagata, and C.M. Ferrario ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury Curr Hypertens Rep 16 3 2014 420
25. A.J. Trask, and C.M. Ferrario Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments Cardiovasc Drug Rev 25 2 2007 162 174
26. M. Iwai, and M. Horiuchi Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis Hypertens Res 32 7 2009 533 536
27. K. Kramkowski, A. Mogielnicki, and W. Buczko The physiological significance of the alternative pathways of angiotensin II production J Physiol Pharmacol 57 4 2006 529 539
28. C.A. McKinney, C. Fattah, C.M. Loughrey, G. Milligan, and S.A. Nicklin Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling Clin Sci (Lond) 126 12 2014 815 827
29. M. Sahara, M. Ikutomi, T. Morita, Y. Minami, T. Nakajima, Y. Hirata, and et al. Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation Cardiovasc Res 101 2 2014 236 246
30. T. Sato, T. Suzuki, H. Watanabe, A. Kadowaki, A. Fukamizu, P.P. Liu, and et al. Apelin is a positive regulator of ACE2 in failing hearts J Clin Invest 123 12 2013 5203 5211
31. N. Parajuli, T. Ramprasath, V.B. Patel, W. Wang, B. Putko, J. Mori, and et al. Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases Can J Physiol Pharmacol 92 7 2014 558 565
32. S. Nagata, J. Kato, K. Sasaki, N. Minamino, T. Eto, and K. Kitamura Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system Biochem Biophys Res Commun 350 4 2006 1026 1031
33. S. Ahmad, J. Varagic, L. Groban, L.J. Dell'Italia, S. Nagata, N.D. Kon, and et al. Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate Curr Hypertens Rep 16 5 2014 429
34. K. Yamamoto, M. Ohishi, T. Katsuya, N. Ito, M. Ikushima, M. Kaibe, and et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II Hypertension 47 4 2006 718 726
35. A. Daugherty, M.W. Manning, and L.A. Cassis Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice J Clin Invest 105 11 2000 1605 1612
36. A. Daugherty, D.L. Rateri, H. Lu, T. Inagami, and L.A. Cassis Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor Circulation 110 25 2004 3849 3857
37. K.K. Ng, and J.R. Vane Some properties of angiotensin converting enzyme in the lung in vivo Nature 225 5238 1970 1142 1144
38. E. Vicaut, and X. Hou Local renin-angiotensin system in the microcirculation of spontaneously hypertensive rats Hypertension 24 1 1994 70 76
39. S. Keidar, R. Heinrich, M. Kaplan, T. Hayek, and M. Aviram Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized ldl: a possible role for interleukin-6 Arterioscler Thromb Vasc Biol 21 9 2001 1464 1469
40. S. Wassmann, T. Czech, M. van Eickels, I. Fleming, M. Bohm, and G. Nickenig Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice Circulation 110 19 2004 3062 3067
41. D. Weiss, J.J. Kools, and W.R. Taylor Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice Circulation 103 3 2001 448 454
42. F. Sugiyama, S. Haraoka, T. Watanabe, N. Shiota, K. Taniguchi, Y. Ueno, and et al. Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system Lab Invest 76 6 1997 835 842
43. C. Hu, A. Dandapat, J. Chen, Y. Liu, P.L. Hermonat, R.M. Carey, and et al. Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression Atherosclerosis 199 2 2008 288 294
44. C. Werner, M. Baumhakel, K.K. Teo, R. Schmieder, J. Mann, T. Unger, and et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection Clin Res Cardiol 97 7 2008 418 431
45. M. Bohm Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now Am J Cardiol 100 3a 2007 38j 44j
46. T. Munzel, and J.F. Keaney Jr. Are ACE inhibitors a magic bullet against oxidative stress? Circulation 104 13 2001 1571 1574
47. E. Chabielska, A. Mogielnicki, K. Kramkowski, and W. Buczko Antithrombotic effect of captopril and enalapril in old rats Pharmacol Rep 57 1 2005 135 137
48. S. Chlopicki, and R.J. Gryglewski Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium Pharmacol Rep 57 Suppl. 2005 86 96
49. R.J. Gryglewski, J. Swies, W. Uracz, S. Chlopicki, and E. Marcinkiewicz Mechanisms of angiotensin-converting enzyme inhibitor induced thrombolysis in Wistar rats Thromb Res 110 5-6 2003 323 329
50. V.I. Kozlovski, M. Lomnicka, A. Fedorowicz, and S. Chlopicki On the mechanism of coronary vasodilation induced by angiotensin-(1-7) in the isolated guinea pig heart Basic Clin Pharmacol Toxicol 100 6 2007 361 365
51. C.M. Ferrario Does angiotensin-(1-7) contribute to cardiac adaptation and preservation of endothelial function in heart failure? Circulation 105 13 2002 1523 1525
52. I. Kucharewicz, R. Pawlak, T. Matys, D. Pawlak, and W. Buczko Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7) Hypertension 40 5 2002 774 779
53. G. Wiemer, L.W. Dobrucki, F.R. Louka, T. Malinski, and H. Heitsch AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium Hypertension 40 6 2002 847 852
54. R.A. Santos, and A.J. Ferreira Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist Cardiovasc Drug Rev 24 3-4 2006 239 246
55. Z.B. Armstrong, D.R. Boughner, M. Drangova, and K.A. Rogers Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model Cardiovasc Res 90 1 2011 165 170
56. Y.B. Sui, J.R. Chang, W.J. Chen, L. Zhao, B.H. Zhang, Y.R. Yu, and et al. Angiotensin-(1-7) inhibits vascular calcification in rats Peptides 42 2013 25 34
57. T.M. Murca, P.L. Moraes, C.A. Capuruco, S.H. Santos, M.B. Melo, R.A. Santos, and et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction Regul Pept 177 1-3 2012 107 115
58. A.J. Ferreira, V. Shenoy, Y. Qi, R.A. Fraga-Silva, R.A. Santos, M.J. Katovich, and et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases Exp Physiol 96 3 2011 287 294
59. C. Schindler ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET Ther Adv Cardiovasc Dis Engl 2008 233 248
60. D.J. Campbell, A. Kladis, and A.M. Duncan Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides Hypertension 23 4 1994 439 449
61. X. Jeunemaitre, J. Menard, J. Nussberger, T.T. Guyene, H.R. Brunner, and P. Corvol Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients Am J Hypertens 2 11 Pt 1 1989 819 827
62. M. Hanssens, M.J. Keirse, P.J. Lijnen, M.J. Kucharski, C. Luyten, and F.A. Van Assche Measurement of individual angiotensin peptides by HPLC-RIA J Biochem Biophys Methods 21 2 1990 103 113
63. G.O. Naik, and G.W. Moe Simultaneous separation of angiotensin and endothelin peptide families by high-performance liquid chromatography: application to the specific radioimmunoassay measurement of angiotensin II or endothelin-1 from tissue J Chromatogr A 870 1-2 2000 349 361
64. G.O. Naik, G.W. Moe, and P.W. Armstrong Specific and non-specific measurements of tissue angiotensin II cascade members J Pharm Biomed Anal 24 5-6 2001 947 955
65. S. Nagata, J. Kato, K. Kuwasako, and K. Kitamura Plasma and tissue levels of proangiotensin-12 and components of the renin-angiotensin system (RAS) following low- or high-salt feeding in rats Peptides 31 5 2010 889 892
66. M. Lortie, S. Bark, R. Blantz, and V. Hook Detecting low-abundance vasoactive peptides in plasma: progress toward absolute quantitation using nano liquid chromatography-mass spectrometry Anal Biochem 394 2 2009 164 170
67. C.E. Bystrom, W. Salameh, R. Reitz, and N.J. Clarke Plasma renin activity by LC-MS/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity Clin Chem 56 10 2010 1561 1569
68. D.L. Chappell, T. McAvoy, B. Weiss, R. Weiner, and O.F. Laterza Development and validation of an ultra-sensitive method for the measurement of plasma renin activity in human plasma via LC-MS/MS Bioanalysis 4 23 2012 2843 2850
69. K.M. Elased, D.R. Cool, and M. Morris Novel mass spectrometric methods for evaluation of plasma angiotensin converting enzyme 1 and renin activity Hypertension 46 4 2005 953 959
70. K.M. Elased, T.S. Cunha, S.B. Gurley, T.M. Coffman, and M. Morris New mass spectrometric assay for angiotensin-converting enzyme 2 activity Hypertension 47 5 2006 1010 1017
71. B. Bujak-Gizycka, J. Madej, P.P. Wolkow, R. Olszanecki, L. Drabik, J. Rutowski, and et al. Measurement of angiotensin metabolites in organ bath and cell culture experiments by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) J Physiol Pharmacol 58 3 2007 529 540
72. L. Cui, K. Nithipatikom, and W.B. Campbell Simultaneous analysis of angiotensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells Anal Biochem 369 1 2007 27 33
73. Q. Ali, Y. Wu, S. Nag, and T. Hussain Estimation of angiotensin peptides in biological samples by LC/MS method Anal Methods 6 1 2014 215 222
74. D. Hildebrand, P. Merkel, L.F. Eggers, and H. Schluter Proteolytic processing of angiotensin-I in human blood plasma PLoS One 8 5 2013 e64027
75. A. Schulz, J. Jankowski, W. Zidek, and V. Jankowski Absolute quantification of endogenous angiotensin II levels in human plasma using ESI-LC-MS/MS Clin Proteomics 11 1 2014 37